Cerecor Inc Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients - Corporate Call Transcript
Ladies and gentlemen, thank you for standing by and welcome to the Cerecor Initial Phase 1B Result for CERC-002 in Moderate to Severe Crohn's Disease Patients Conference Call.
At this time, all participants are in a listen-only mode. (Operator Instructions).
I would now like to turn the conference over to your speaker host today, Mr. Schond Greenway. Please go ahead.
Thank you, [Olivia]. Good day, everyone and thank you for joining us today to discuss the initial results from our Phase 1b proof of concept study evaluating CERC-002 at investigational first-in-class fully human anti-LIGHT monoclonal antibody in adult patients with moderate to severe Crohn's disease.
Speaking on the call today, we have Mike Cola, our Chief Executive Officer; Dr. Gary Neil, our Chief Scientific Officer; Dr. Jeffrey Wilkins, our Chief Medical Officer; and Dr. Gerald Dryden, Study Investigator and Professor of Medicine and Director of the Inflammatory Bowel Disease Program at the University of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
